North CarolinaPrevention Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Prevention are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Estimate Benchmark Distance to Benchmark
Adults age 65 and over who received an influenza vaccination in the last flu season 71.1 70.3 Achieved: 1% better
Children ages 19-35 months who received 3 or more doses of hepatitis B vaccine 94.5 96.4 1.9%
Children ages 19-35 months who received 1 or more doses of varicella vaccine 93.6 95.7 2.2%
Adults who received a blood cholesterol measurement in the last 5 years 80.1 82.3 2.6%
Children ages 19-35 months who received 1 or more doses of measles-mumps-rubella vaccine 93.3 96.4 3.2%
Adolescents ages 16-17 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years 92.1 95.9 4.0%
Adults age 65 and over who ever received pneumococcal vaccination 75.0 78.7 4.7%
Children ages 19-35 months who received 4 or more doses of diphtheria-tetanus-pertussis vaccine 86.0 90.6 5.1%
Long-stay nursing home residents who were assessed for pneumococcal vaccination 92.8 98.0 5.3%
Home health patients who had influenza vaccination during flu season 79.9 84.8 5.8%
Long-stay nursing home patients who were assessed and appropriately given the seasonal influenza vaccine 88.2 94.1 6.3%
Children ages 19-35 months who received 3 or more doses of polio vaccine 91.0 97.3 6.5%
Short-stay nursing home residents who were assessed for pneumococcal vaccination 88.5 95.3 7.1%
Adolescents ages 13-15 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years 87.0 95.2 8.6%
Short-stay nursing home patients who had flu vaccination appropriately given 84.5 92.9 9.0%
Measures That Are Close to Benchmark
Measure Estimate Benchmark Distance to Benchmark
Home health patients who had pneumococcal polysaccharide vaccination 76.7 86.1 10.9%
Adults ages 18-64 at high risk (e.g., COPD) who received an influenza vaccination in the last flu season 42.0 47.8 12.1%
Adults ages 18-64 at high risk (e.g., COPD) who ever received pneumococcal vaccination 37.9 44.8 15.4%
Adolescents ages 16-17 who received 1 or more doses of meningococcal conjugate vaccine 77.7 96.2 19.2%
Adolescents ages 13-15 who received 1 or more doses of meningococcal conjugate vaccine 74.2 95.4 22.2%
Cervical cancer diagnosed at advanced stage (all invasive tumors) per 100,000 women age 20 and over 9.7 7.6 28.3%
Breast cancer diagnosed at advanced stage (regional, distant stage, or local stage with tumor greater than 2 cm) per 100,000 women age 40 and over 93.5 72.8 28.5%
Colorectal cancer diagnosed at advanced stage (tumors diagnosed at regional or distant stage) per 100,000 population age 50 and over 65.1 47.2 38.0%
Measures With No Available Benchmark Information or Supplemental Measures
Measure Estimate Benchmark Distance to Benchmark
Composite measure: Children ages 19-35 months who received all recommended vaccines 77.8
Adolescents ages 13-15 years (excluding adolescents who have had varicella) vaccinated with at least 2 doses of varicella 78.5
Adolescent aged 13-15 years who received 3 or more doses of human papillomavirus (HPV) vaccine 33.0
Adolescent ages 16-17 years who received 3 or more doses of human papillomavirus (HPV) vaccine 38.1